drugset / Trial / NCT05575076
Open-label Extension for Phase 3 Clinical Trials of Simufilam
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
Timeline
- Start
- 2022-11-07
- Primary completion
- 2025-01-31
- Completion
- 2025-01-31
Outcome
Outcome not reported
Stopped (Business): “sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Simufilam | Small molecule | 100 mg | Oral |